Skip to Main Content

Paper Details

Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus.
Heliyon
2
2023
COVID-19, Delta, Omicron, Omicron,, RAbD, RosettaAntibodyDesign, SARS, SARS-CoV, SARS-CoV-1, SARS-CoV-2, SARS-CoV-2 spike protein, SARS-CoV-2 virus, South African spike protein variants, Wuhan, antibody 80R, human, spike protein
Author NameAffiliation
Vijaya L SimhadriCenter for Biologics Evaluation and Research U.S. FDA
Vijaya L SimhadriCenter for Biologics Evaluation and Research U.S. FDA
Sagar D KhareThe State University of New Jersey
Sagar D KhareInstitute for Quantitative Biomedicine, The State University of New Jersey
Roland L DunbrackInstitute for Cancer Research, Fox Chase Cancer Center
Jeffrey J GrayJohns Hopkins University
Jeffrey J GrayJohns Hopkins University
Jeffrey J GraySidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Jeffrey J GrayInstitute for Nanobiotechnology, Johns Hopkins University
Jeffrey J GrayJohns Hopkins University
Jeffrey J GrayJohns Hopkins University
Jeffrey J GraySidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Jeffrey J GrayInstitute for Nanobiotechnology, Johns Hopkins University
  • 1 - 13

Datasets

Release 1.2